Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Tafasitamab for R/R DLBCL

Ulrich Jäger • 28 Jun 2021
EHA 2021
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Tafasitamab

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on the use of tafasitamab, a CD19-targeted monoclonal antibody, and immune checkpoint inhibitors for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Ulrich Jäger

2:33
The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
Ulrich Jäger • 16 Feb 2024
1:20
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
Ulrich Jäger • 16 Feb 2024
3:31
The role of lymphodepletion in CAR T-cell therapy: current knowledge & the need for personalization
Ulrich Jäger • 16 Feb 2024
0:58
CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger • 10 Feb 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals